Compare KBH & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBH | RLAY |
|---|---|---|
| Founded | 1957 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.3B |
| IPO Year | 1994 | 2020 |
| Metric | KBH | RLAY |
|---|---|---|
| Price | $52.22 | $17.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $56.17 | $19.50 |
| AVG Volume (30 Days) | 1.1M | ★ 3.7M |
| Earning Date | 03-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $4,547,002,000.00 | $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.23 | $324.03 |
| P/E Ratio | $101.00 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $44.03 | $3.03 |
| 52 Week High | $68.71 | $17.50 |
| Indicator | KBH | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 71.94 |
| Support Level | $48.89 | $11.68 |
| Resistance Level | $52.79 | N/A |
| Average True Range (ATR) | 1.83 | 0.94 |
| MACD | 0.05 | 0.31 |
| Stochastic Oscillator | 34.56 | 96.65 |
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.